ClinicalTrials.Veeva

Menu

Effect of Genetic Polymorphism on Capecitabine-Induced Toxicity in Egyptian Cancer Patients

A

Ain Shams University

Status

Enrolling

Conditions

Breast Cancer
Colorectal Cancer

Treatments

Drug: Capecitabine-based chemotherapy

Study type

Observational

Funder types

Other

Identifiers

NCT06765252
4/2024ONCO16
281

Details and patient eligibility

About

The goal of this observational study is to study the effect of a single nucleotide polymorphism in the CES1 gene (rs2244613) on capecitabine-induced toxicity in Egyptian cancer patients. This study will help in understanding the interindividual variability in the CES1 gene and the effect of a single nucleotide polymorphism in this gene (rs2244613) on capecitabine-induced toxicity in participants already taking capecitabine-based chemotherapy as part of their regular medical care.

Enrollment

80 estimated patients

Sex

All

Ages

18+ years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • Patients with breast or colorectal cancer receiving capecitabine-based chemotherapy
  • Age > 18 years
  • ECOG PS 0-2.

Exclusion criteria

  • Patients treated with irinotecan
  • Lack of physical integrity of the upper gastrointestinal tract
  • Patients with malabsorption syndrome
  • Patients having inability to take oral medication
  • Patients with poor performance status
  • Patients with chronic diarrhea as ulcerative colitis or Crohn's disease

Trial contacts and locations

1

Loading...

Central trial contact

Raghad Nassar, Teaching Assistant

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2025 Veeva Systems